NCT00383903View on ClinicalTrials.gov

Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa

PHASE2CompletedINTERVENTIONAL
Enrollment

472

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions
Infections, Rotavirus
Interventions
BIOLOGICAL

HRV vaccine

Two or three oral doses

Trial Locations (6)

2

GSK Investigational Site, Pretoria

GSK Investigational Site, Pretoria North

GSK Investigational Site, Sunnyside, Pretoria

0250

GSK Investigational Site, Brits

0208

GSK Investigational Site, Ga-Rankuwa

0145

GSK Investigational Site, Rooihuiskraal

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00383903 - Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa | Biotech Hunter | Biotech Hunter